A new anticopper drug, tetrathiomolybdate (TM), developed for Wilson's disease, is a very promising antiangiogenic agent. Copper levels lowered into an antiangiogenic window by TM have shown efficacy against cancer in a variety of animal models as well as in patients. The only significant toxicity so far results from overtreatment and excessive bone marrow depletion of copper. The resulting anemia and/or leukopenia is easily treatable by dose reduction or drug holiday. The underlying concept for TM efficacy as an anticancer agent is that when the body's copper status is in the window, cellular copper needs are met and toxicity is avoided. Copper status is relatively easily monitored by following serum ceruloplasmin, a copper-containing protein secreted by the liver at a rate dependent upon the amount of copper in the liver available to incorporate into the protein. The authors speculate that the copper level is a primitive angiogenesis and growth-signaling regulator that has been retained throughout evolution.
The past decade has seen a crescendo of interest and activity in the testing of antiangiogenic agents for the treatment of cancer. [1] [2] [3] [4] [5] [6] More recently, a cautious note has been struck, in that it is being said that most antiangiogenic agents have limited applicability as sole therapy in a variety of malignancies, 7 that achieving any real success is years away, 8 and that their muchhyped "magic bullet" potential remains largely unfulfilled. 9 Because most of the agents being tested are directed at single angiogenic molecules or their receptors, it appears that tumors are generally able to find alternative paths to stimulate blood vessel growth. Our interest in using the copper-lowering drug tetrathiomolybdate (TM) as an antiangiogenic agent is due in part to its global effects. We hypothesize that it may have more generalized applicability than most singletarget antiangiogenic agents because it appears that copper at relatively high levels is required for the function of many proangiogenic molecules. Thus it appears, at least as of this writing, that lowered copper levels may provide a more global inhibition of angiogenesis than previously studied angiogenic drugs.
We will begin with a review of some of the basics of angiogenesis and cancer, and of angiogenesis and copper. This will be followed by a description and characterization of the presently available copper-lowering drugs. We first review the studies using TM in cancer and other diseases of neovascularization, and then we review the molecular mechanisms of TM action. We conclude with a postulate on why copper might be a global regulator of angiogenesis and growth.
Angiogenesis and Cancer
In the early 1970s, Judah Folkman began to publish his ideas about the need for angiogenesis for cancer growth and how this need might be an Achilles' heel of cancer, since most adult tissues do not require angiogenesis. 10, 11 Although Folkman continued to publish in this area, 12, 13 his ideas did not seem to attract much interest at first. However, over the past 15 years, scientists have seized on the potential of antiangiogenesis for cancer therapy, and research has led to the identification of a large number of factors that either stimulate or inhibit angiogenesis, and interact with one another in the process. An increased understanding of the molecular mediators of tumor and normal angiogenesis has spurred the development of drugs that are designed to interfere with angiogenesis in one manner or another. Table 1 provides a partial list of the angiogenic factors, and Table 2 emphasizes the interaction among many angiogenic factors. These factors are normally called upon at various times during embryogenesis and development for tissue growth and organ development. Many of them are also available to respond to tissue damage and repair during injury or infection. It appears that tumors, either by elaborating on some of these proangiogenesis factors themselves or by recruiting normal cells that then elaborate on the factors, are able to take advantage of a large number of proangiogenic molecules for the purposes of angiogenesis. Of course, the large number of proangiogenic factors, and their interactions, make the process exceedingly complex and, consequently, the problem of developing a generally effective antiangiogenesis agent more difficult. At one extreme, if 1 antiangiogenic drug targeting 1 angiogenic molecule would be effective in significantly inhibiting angiogenesis in a large number of tumor types, the whole concept of antiangiogenic cancer therapy would be greatly simplified. In contrast, at the other extreme, the great redundancy, complexity, and interaction of numerous proangiogenic molecules makes it extremely difficult to target 1 molecule and expect it to produce a long-lasting effect on tumor growth in a large variety of tumors. Simply put, if tumors are stopped at one route to angiogenesis, they often seem to have, or be able to recruit, others. It is possible that this redundancy, having been essential in normal growth and development and favored in evolution, is exploited by tumors in eliciting pathologic angiogenesis.
Angiogenesis and Copper
In the 1980s, considerable work was done showing that copper was an angiogenic stimulant. 14, 15 This was done by placing copper or molecules containing copper in the cornea of the rabbit and showing that angiogenesis occurred around such a pellet, whereas it was absent in control pellets not containing copper. 14 The copper-containing molecules could be organic, such as for example the copper-containing protein ceruloplasmin, and still stimulate angiogenesis. 15 Later, another type of study was done that was even more relevant to the topic under consideration in this review. 16 Rabbits were rendered moderately copper deficient by a combination of penicillamine therapy and a low copper diet. Then, angiogenic substances were put into the cornea. In normal rabbits, the angiogenic agent, prostaglandin E 1 , produced a marked angiogenic response. This effect of prostaglandin E 1 was markedly reduced in copper-deficient rabbits. 16 Brem and colleagues 17, 18 pursued this line of investigation further. Syngeneic rabbit VX2 carcinoma cells were implanted in the brains of copper-deficient and normal rabbits. The growth of the tumor implant in the control animals was robust and showed brisk angiogenesis and profuse invasion of blood vessels into the surrounding normal brain tissue. On the other hand, tumor growth in the brain of the copperdeficient animals was markedly reduced, and there was no invasion of the tumor or blood vessels into the normal brain tissue. Although these results appeared promising, there was no survival advantage in the copper-deficient animals, and this seems to have discouraged these investigators, who did not pursue the work further.
In the 1990s, Brewer and colleagues [19] [20] [21] developed TM as an anticopper drug for the treatment of Wilson's disease. TM turned out to be a remarkably quick acting, potent, and safe anticopper drug. Because of these properties, we became interested in the application of TM to possible antiangiogenic therapy in cancer. That work will be detailed in much of the remainder of this review.
Copper-Lowering (Anticopper) Drugs
Although many chemical agents will bind copper or otherwise affect its metabolism, at this time we consider only 4 drugs to be clinically effective anticopper agents: penicillamine, trientine, zinc, and TM. All of these drugs have the following characteristics: (1) they have seen considerable use in humans, (2) they produce a negative copper balance, and (3) they are effective in the treatment of Wilson's disease.
Penicillamine
Penicillamine was introduced in 1956 22 and was the first oral drug for the treatment of Wilson's disease. For a long time, it was the only drug available for this purpose, and a generation or two of Wilson's disease patients owe their lives to its effectiveness. Penicillamine acts by being a reductive chelator of copper. Because most copper is bound to proteins, the reduction step greatly decreases the affinity of copper for protein and allows it to be chelated by penicillamine. The chelated copper is then excreted primarily in the urine.
Penicillamine is an aggressive drug and produces a negative copper balance of several milligrams per day in Wilson's disease patients in the first few weeks of treatment. 23 Penicillamine is effective in the sense that it will always produce a negative copper balance, and after weeks to months of continuous treatment, it will prevent disease progression from additional copper toxicity. Penicillamine, however, has 2 serious drawbacks. One is that it has a very long list of toxicities. 23, 24 These include bone marrow suppression, kidney disease, autoimmune manifestations, and connective tissue disorders, among others. The second major drawback is that about 50% of the patients who present with neurological Wilson's get worse neurologically if treated initially with penicillamine. 25 This is probably due to the strong effect of the drug on mobilizing hepatic copper, flushing it through the bloodstream and temporarily further elevating brain copper. One out of 4 patients with the neurological presentation of Wilson's disease will have further permanent neurological disability if treated initially with penicillamine.
Trientine
In 1982, trientine was introduced as a drug to be used for patients who were intolerant to penicillamine. 26 Trientine acts in a manner similar to penicillamine in that it will chelate copper and cause an increase in urinary excretion. Trientine is a less aggressive drug than penicillamine and does not cause the huge bolus of urine copper and the large initial negative copper balance that penicillamine does. However, it is effective and produces enough of a negative copper balance to eventually detoxify copper in the Wilson's disease patient.
Trientine has never had a formal toxicity study, but based on experience it seems considerably safer than penicillamine. 27 It does share in producing some of the autoimmune effects of penicillamine and can produce bone marrow suppression and proteinuria. It is unknown whether it shares the neurological worsening effect of penicillamine when used in Wilson's disease patients presenting with neurological disease.
Zinc
In 1978, Brewer and colleagues 28, 29 observed that zinc therapy in sickle cell anemia produced copper deficiency on a regular basis. Because they were aware of the toxicity of penicillamine, this finding led them to explore zinc treatment for Wilson's disease, which led to the subsequent development of zinc as an anticopper agent for the treatment of this disease. 24 Table 2 
. Multiple Interactions Among Positive Regulators of Tumor Angiogenesis
Multiple interactions among the positive tumor angiogenic factors are shown to illustrate the complexity and potential redundancy of their participation in tumor angiogenesis. VEGF = vascular endothelial growth factor, FGF = fibroblast growth factor, HGF = hepatic growth factor, SF = scatter factor, PTN = pleiotrophin, MK = midkine, IL = interleukin, TGF = transforming growth factor, TNF = tumor necrosis factor, EGF = epidermal growth factor, PDGF = platelet-derived growth factor, Ang-1 = angiopoietin-1, PECAM = platelet endothelial cell adhesion molecule, Coll = collagen, LM = laminin, FN = fibronectin, SPARC = secreted protein acidic and rich in cysteine, GAG/PG = glycosaminoglycan/proteoglycan, PGE = prostaglandin E, 12-HETE = 12-hydroxy eicosatetraenoic, PKC = protein kinase C.
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group in the Netherlands led by Hoogenraad worked on zinc therapy independently at about the same time. [32] [33] [34] Zinc acts by inducing a high level of intestinal cell metallothionein, which then binds food copper and copper in endogenous intestinal secretions. [35] [36] [37] [38] The Zn-metallothionein complex is held in the intestinal cell, which has about a 6-day life span, and then sloughs into the lumen of the intestine. The copper is then carried out in the stool. The effect of zinc is to produce a mucosal block of copper absorption. Our group has conducted a large series of studies of zinc therapy for Wilson's disease, which eventually led to a new drug application and approval by the FDA in 1997. Zinc is a fully effective treatment for the maintenance therapy of Wilson's disease. It is also recommended for treating presymptomatic patients, 31, 39 as well as women with Wilson's disease during pregnancy. 40 The only side effect of zinc is occasional gastric irritation immediately following ingestion of the drug.
TM
As discussed earlier, penicillamine is contraindicated for the treatment of the Wilson's disease patient presenting with neurological manifestations because of the high risk of neurological worsening. 25 Theoretically, at least, trientine shares that risk with penicillamine because it acts in a similar manner. Zinc, in our opinion, is too slow acting to be used for acutely ill patients. The need for an additional anticopper drug to fill this therapeutic hiatus stimulated our development of TM.
The story of the development of TM into a bona fide anticopper drug for use in humans has a number of interesting chapters. First, it was discovered that in certain pastures in New Zealand and Australia, ruminants, but not nonruminants, developed a disease syndrome. 41 After a time, it was realized that the disease syndrome was copper deficiency. 42, 43 The soil of these pastures was investigated and found to be very high in molybdenum, and of course the grass of the pastures incorporated this molybdenum in large amounts. Molybdenum fed to ruminants reproduced the copper deficiency syndrome, 44 but not when fed to nonruminants. 45, 46 The next chapter was the realization that the rumen is sulfur-rich due to the high disulfide content of cellulose of grass, and the rumen was converting the molybdenum into thiomolybdate compounds. 47 Thiomolybdates when administrated to nonruminants turned out to be potent anticopper agents. [48] [49] [50] There can be 1 to 4 sulfur substitutions on the molybdenum molecule, and it turned out that the tetra-substituted compound, TM, was the most potent anticopper agent.
TM turned out to have rather remarkable anticopper effects, and would kill animals rather quickly from copper deficiency if administered without copper supplementation. 48, 49 However, all of the apparent toxicities of TM could be prevented simply by copper supplementation-in other words, they were due to copper deficiency. 50 It seemed to us that TM might offer the ideal fastacting and safe anticopper drug for the initial treatment of the neurologically presenting Wilson's disease patient. There was enough veterinary literature on its use to allow the FDA to permit us to use the drug for an 8-week initial treatment trial for neurologically presenting patients, and it proved to be very effective for these patients. [19] [20] [21] In 55 such patients in an open label study during TM treatment, only 2 showed initial neurological deterioration, in contrast to the 50% that would show deterioration if treated with penicillamine. 21 Our interpretation of these data is that there is an occasional patient who by virtue of the natural history of the disease will deteriorate, but penicillamine has an additional, drug-induced effect that causes a very high frequency of neurological worsening.
The mechanism of action of TM is different from that of other anticopper drugs. It forms a tripartite complex with protein and copper. [48] [49] [50] [51] We give part of the daily TM dose with meals, where the complex is formed with food copper and endogenously secreted copper, and that copper is not absorbed. [19] [20] [21] We give part of the daily dose away from food. This TM ingested between meals is readily absorbed and forms a complex with serum albumin and loosely bound copper, making that copper unavailable for cellular uptake, rendering it nontoxic. [19] [20] [21] This complex accumulates in the blood to a certain extent, as it clears slowly, making serum copper no longer useful to evaluate copper status in the initial stages of TM therapy.
We have encountered 2 toxicities from TM in the Wilson's disease work. 21 One is dose-dependent bone marrow suppression due to overtreatment. This is usually manifested as anemia, occasionally with mild leukopenia, and both are easily overcome by a brief drug holiday or a reduction in dose. This appears to be due to a high requirement of the bone marrow for copper for both heme syntheses and cell proliferation. Thus, even in the Wilson's disease patient, where copper stores are very high, TM is capable of causing copper depletion in the bone marrow compartment.
The second side effect we have seen appears to be restricted to Wilson's disease patients. In about 10% of patients, we observe a dose-related increase in transaminase enzymes in the serum. These patients already have liver disease at the onset of therapy, and it appears that the mobilization of copper causes a mild further transaminase elevation. Again, this side effect is easily reversible by a drug holiday or reduction of dose. We have not seen this side effect in any other patients except those with Wilson's disease, and we have not seen it in any animal studies.
Preclinical Cancer Studies of TM Therapy

Rodent Studies
The first study aimed at investigating the potential efficacy of TM as an anticancer agent used a syngeneic murine MCA 205 sarcoma cell line injected subcutaneously. As soon as tumors were palpable under the skin, half of the mice were started on treatment with TM at a once daily dose of 1.25 mg/day by gavage. Over a 3-week period, the rate of growth of the tumors in the TM-treated animals was significantly less than in the controls. At the time of sacrifice, the tumors were dissected out, weighed, and shown to be significantly smaller in the TM-treated versus control animals (Brewer, unpublished data).
Another useful outcome of this study was the development of serum ceruloplasmin as a surrogate marker of copper status. As previously mentioned, while a patient or animal is on TM therapy serum copper cannot be directly used to measure copper status because the complex of TM, copper, and albumin builds up in the blood and is only slowly cleared. This results in a high serum copper that is a spurious reflection of the body's bioactive copper status. Instead, we used serum ceruloplasmin as a surrogate marker. The ceruloplasmin protein is synthesized by the liver and contains 6 to 7 molecules of copper. The secretion of ceruloplasmin by the liver into the blood is dependent on the availability of copper. 52 The ceruloplasmin measurement is thus a good reflection of the availability of copper to a tumor.
To probe in more detail the effects of TM on the onset of angiogenesis in a developing tumor, we used the MMTV-Her2/neu transgenic mouse model, developed by the Muller laboratory. 53 In this model, overexpression of the rat neu gene under the control of the MMTV promoter renders the females prone to mammary cancers that develop in nulliparous animals at a median age of 205 days. Beginning about day 100, half of the mice were treated with TM by once daily gavage of a dose of 0.7 mg and half were vehicletreated controls. By day 270, 18 of the 22 control animals had developed large and often multiple breast tumors, but none of the 15 TM-treated animals had developed detectable tumors. 54 This result was highly statistically significant. At necropsy, TM-treated animals showed multiple small clusters of cancer cells in their mammary glands. Five treatment animals released from TM therapy all had palpable tumors within 12 days. As a pilot study, we also treated tumorbearing control animals with TM, and in 3 out of 5 cases tumor volume was significantly reduced (Pan et al, unpublished data). This study provided encouraging evidence that TM may be a promising agent for well-established tumors; however, most strikingly, its preventive effect was so drastic that it suggests that we might be able to prevent incipient primary tumors or perhaps micrometastatic disease from developing into macroscopic tumors.
Subsequent studies have also been carried out on a murine squamous cell model of head and neck cancer. 55 When the SC3 cells are implanted under the tongue of mice, simulating the orthoptic environment of human squamous cell carcinoma of the head and neck, tumors grow extremely rapidly, such that within 7 days the animals must be sacrificed for humane reasons. TM proved to be remarkably effective in this model, strongly inhibiting the growth of this tumor. As part of this work, analyses of microvessel density detected by factor VIII showed that microvessel density was markedly inhibited in the TM-treated group. 55 This squamous cell carcinoma model was subsequently implanted in the flank, where it grows more slowly. Over a 54-day period, TM was shown to markedly inhibit the growth of this tumor in the flank compared to controls (unpublished data). Taken together, these results suggest that TM may be effective in treating squamous cell carcinoma of the head and neck, both as an adjunct to other treatments and in a chemoprevention setting.
The Lewis lung high metastatic cancer model in mice was employed to investigate whether TM could potentiate the antitumor effects of radiotherapy, which is the main form of treatment for many human lung cancers that are unresectable. 56 In this study, TM alone was shown to have a strong inhibitory effect on tumor growth, as does radiation therapy. The two combined produced a roughly additive effect on inhibiting the growth of this aggressive cancer line. This work is important because it suggests that TM may be combined with radiotherapy to elicit an increased response, without evidence of increased toxicity of the combination therapy.
Seeking to understand the specific molecular mediators of the antiangiogenic effects of TM, TM treatment was evaluated in an aggressive human breast cancer xenograft developed by orthoptic implantation in the mammary fat pad of an inflammatory breast cancer cell line (Pan et al, unpublished data). By 35 days, tumors had begun to grow rapidly in control animals but were nondetectable in TM-treated animals. TM was then stopped for 48 hours, and subsequently treatment was resumed at one third the initial dose in one group of animals and two thirds the initial dose in another group of animals. Tumor growth was shown to be inhibited in a dose-dependent manner in these animals.
Canine Cancer Studies
In collaboration with a group at the University of California in Davis, Kent et al 57 carried out a phase I/II study of TM therapy in 13 dogs that spontaneously developed cancer. The dogs had a variety of advanced cancers. They were treated with a relatively high induction dose of TM, generally about 5 to 10 mg/kg. Then, after ceruloplasmin reached a target of about 25% to 50% baseline, the dogs were reduced to a maintenance dose, which generally ranged from 2 to 5 mg/kg but was adjusted to maintain the animals in the target ceruloplasmin range.
Nine of the 13 dogs achieved ceruloplasmin reduction for an adequate length of time (1 month) to allow evaluation of tumor response. 57 Of these 9 dogs, 5 had no response to treatment whereas 4 had tumor responses characterized as disease stabilization or tumor reduction. In 2 cases, the effect of TM was remarkable. One dog that had osteosarcoma and lung metastases had reduction in the tumor metastases in the lung as well as disappearance of paraneoplastic hypertrophic osteopathy. This dog had a 9-month period of freedom from progression and then died from uremia secondary to urinary tract obstruction without disease progression in the lung. The second dog had an anal gland carcinoma with extensive metastatic disease and is still alive and doing well 1 year after initiation of TM therapy, with stable disease.
Clinical Studies Phase I/II Trial of TM Cancer Therapy
We carried out a phase I study of 42 patients with 20 different diagnoses of advanced and metastatic cancers. In general, to be eligible, these patients had to have failed other effective therapies and had progressive disease over the months preceding their entry into the study. Patients were placed on induction doses of TM ranging from 20 mg 3 times daily with meals and 60 mg at bedtime, to 60 mg 3 times daily with meals and 60 mg at bedtime. The objective was to decrease their ceruloplasmin levels to a range of 5 to 15 mg/dL (normal = 20 to 35 mg/dL). Patients were considered evaluable for freedom from progression if it was possible to follow them long enough to have ceruloplasmin levels in the target range for 2 months.
At the time we published our first article, 58 18 patients had been studied and 6 were considered evaluable. Of these 6, all had freedom from progression for a significant period of time and 1 had regression of her disease.
Subsequently, this study has been expanded to 42 patients of whom a total of 18 were evaluable. 59 The average freedom from progression was 11 months and the median was 6 months. Several patients did extremely well, far exceeding the expected clinical course for their stage of disease and the time since diagnosis of metastatic disease. One patient with metastatic breast cancer had stable disease for nearly 3 years. A patient with metastatic chondrosarcoma of the rib presumed secondary to radiation therapy for a remote breast cancer has had stabilization of her disease for 3.5 years and is still doing well without disease progression by standard criteria.
Measures of quality of life showed that during the period of TM induction, the quality of life of these patients was progressively deteriorating as the tumors were slowly progressing. After induction of copper deficiency, however, and during TM treatment, the quality of life stabilized for all dimensions of the SF-36 instrument. The differences in quality of life between the 2 periods were highly statistically significant. 59
Overview of TM Cancer Therapy
At this point, we speculate that TM as a sole therapy may be efficacious in situations where the overall tumor burden is small, such as minimal disease or micrometastatic disease. A dramatic illustration of that is the long-term prevention of invasive growth of the incipient tumors in the Her2/neu mouse model. 54 These data coupled to some preliminary positive findings in human studies suggest specific features of design for future studies of TM. It suggests that TM may work well as long-term follow-up maintenance therapy or combination therapy with other modalities that reduce tumor burden, such as surgery, chemotherapy, and radiation therapy. It also suggests a possible eventual use for prevention of overt tumor development in patients who are genetically predisposed to cancer if the safety profile remains good.
TM also appears to have some efficacy as sole therapy in some patients with large tumor burdens from advanced and metastatic disease, as suggested by the freedom from progression observed in the phase I study. 58, 59 However, most of these patients were observed to eventually progress. We surmise that in large tumor masses, there is an increased probability of emergence of resistance to the angiogenic inhibition of copper deficiency. It is possible, given our experience so far, that some patients with advanced metastatic cancer will have durable disease stability or even responses on TM therapy alone. Longer follow-up time in phase II studies presently under way, and more experience, will help discern whether certain tumor types are particularly susceptible to TM therapy.
In summary, TM as sole therapy is expected to have some as yet undetermined efficacy, most likely in situations where the overall tumor burden is small. This suggests that the combination of TM with modalities that rapidly reduce the tumor burden and subsequent maintenance therapy with TM alone are all plausible settings in which TM may prove efficacious, but these studies are just beginning.
Studies of TM Therapy in Other Diseases of Neovascularization
Besides cancer, there are other diseases that appear to require angiogenesis as part of their pathogenesis, and for which TM therapy might be beneficial. One of these is rheumatoid arthritis. The pannus that grows into the joint is very vascular, and the rationale is that by reducing angiogenesis, the rheumatoid arthritis will be improved. It is possible that the efficacy of penicillamine therapy in rheumatoid arthritis, never well understood, is due to lowered copper availability, perhaps lowered availability in the confines of the joint space. We now have a plan and clinical protocol to evaluate TM therapy in rheumatoid arthritis.
Another disease of neovascularization of great public health importance is diabetic retinopathy, a very common cause of blindness. We have initiated preclinical studies of retinopathy (not due to diabetes in the animal model presently under study), with encouraging preliminary results. With continued positive results in animal models, we plan on initiating a clinical trial of TM in diabetic retinopathy.
Another relevant disease is wet-type macular degeneration, which is a disease of neovascularization of the choroidal vessels of the eyes and is another common cause of blindness. In collaboration with an ophthalmologist, we carried out a pilot study of TM on 10 patients with wet-type macular degeneration. We saw progression of the disease in many patients in this trial during the period of effective TM-induced copper deficiency, and thus we concluded that it was a negative study. Because the choroidal vasculature is qualitatively different from the retinal vasculature, it is possible that retinopathy, but not macular degeneration, will be treatable with this approach.
There are other possible kinds of neovascularization that might be treatable by TM. One possible therapeutic target is psoriasis, since the psoriatic lesion is highly vascularized.
Molecular Mechanisms of the Inhibition of Angiogenesis by TM: A Work in Progress
An extensive body of evidence from several laboratories supports the idea that the anticancer effects of TM therapy are mediated, at least in part, through an antiangiogenic effect. The mechanism that seems likely is that a number of proangiogenic factors require normal levels of copper for activity. 60 Copperdependent angiogenic factors include vascular endothelial growth factor (VEGF), 4, 61 fibroblast growth factor (FGF), [62] [63] [64] angiotropin, 65 angiogenin, 66 secreted protein acidic and rich in cysteine, 67 and a number of other factors. 68 The large number of potentially copperdependent factors suggests that TM may act as a global angiogenesis inhibitor. In support of this concept, during TM therapy in animals and humans, a significant reduction in circulating levels of VEGF, FGF2, interleukin-6 (IL-6), and IL-8 has been documented (Pan et al, unpublished data).
However, because established tumors ultimately escape from TM's effect and progress, we assume that some angiogenic factors or mechanisms are not susceptible to copper-lowering therapy. Thus, the efficacy of TM on particular tumors will probably ultimately depend on the copper dependency of the net angiogenic activity of the tumor at the time TM therapy is initiated, and on whether and when the tumor is able to effect new, non-copper-dependent angiogenic signals. Another corollary of this line of reasoning is that the degree of copper dependence of the endothelium and stroma of certain metastatic sites to form new vessels may modulate whether a given micrometastatic focus will be successful at a particular site, in a copperdeficient environment. Thus, in a departure from conventional evaluation of extent of disease in oncology, we suggest that descriptive patterns and quantitative evaluation of disease in a variety of metastatic sites may help illuminate this issue.
A Postulate on Why Copper May Be a Global Regulator of Angiogenesis and Growth
As discussed above, many angiogenic factors appear to be copper dependent. This possibly global effect on angiogenic factors appears to result in widespread efficacy of TM therapy in numerous preclinical cancer models and perhaps in other diseases of neovascularization.
A legitimate question that can be asked is, Why should copper have evolved into this key role involving regulation of angiogenesis and growth factors? Other metals such as zinc, iron, magnesium, and calcium play crucial roles in the normal functioning of unicellular and higher organisms as well, so why copper for this key regulatory role?
Our hypothesis is that copper is more widely variable in its bioavailability in the environment than other metals. A literature search, admittedly limited so far, indicates that copper is much more variable in soils around the world than other metals used by organisms. [69] [70] [71] [72] This is further supported by the much more common frequency of copper deficiency than other metal deficiencies in grazing animals. [73] [74] [75] [76] [77] Grazing animals, of course, obtain their nutrients from vegetation growing in the soil, and if the soil varies in content of a given mineral, so will the grass and other vegetation. 78 It appears that deficiency of copper in vegetation in certain regions is much more common than deficiency of other metals, leading to a higher frequency of copper deficiency in grazing animals than deficiencies of other metals.
Our hypothesis is that because soils vary greatly in bioavailable copper content, primitive organisms, all of which had evolved a dependence on copper for certain key functions, evolved a system of growth regulatory functions depending on copper availability. If plenty of copper is available, the organism grows. If copper is very limited, the organism "hunkers" down, and survives as long as possible, but does not dissipate its resources by attempting to grow.
Yeast is an example of an organism that appears to reflect some of these concepts. Yeast is dependent on copper for many key protein functions and has a very elaborate genetic system for acquiring copper from the environment. [79] [80] [81] [82] [83] [84] However, in the absence of copper, yeast switches from an aerobic to an anaerobic metabolism, and growth is strongly inhibited.
In the fungus Podospora anserina, a transcription factor called grisea signals growth. Grisea activation is copper dependent, so that in the presence of copper, growth occurs, but not in its absence. [85] [86] [87] We hypothesize that these primitive regulatory growth signals have been retained throughout evolution and may account for the copper dependence of many angiogenic and growth factors. This hypothesis is also consistent with the strong teratogenic effect of copper deficiency, much more pronounced than with other metal deficiencies. Because the fetus is extremely dependent on a timely cascade of active angiogenic and growth factor signaling, a reduction in activity of a large number of these factors in the setting of copper deficiency would be expected to have drastic teratogenic effects.
